Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829981 | 1.00 | TLR8 (0.41) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17829984 | 0.79 | TLR8 (0.56) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17829978 | 0.79 | TLR8 (0.60) | TLR8ADORA1CYP2D6DRD1HTR2A | |
| SCHEMBL17829988 | 0.79 | TLR8 (0.60) | TLR8ADORA1CYP2D6DRD1HTR2A | |
| SCHEMBL22448318 | 0.79 | TLR8 (0.36) | TLR8CYP2D6ADORA2AKCNH2TLR7 | |
| SCHEMBL17829992 | 0.79 | TLR8 (0.36) | TLR8CYP2D6ADORA2AKCNH2TLR7 | |
| SCHEMBL21536319 | 0.78 | KCNH2 (0.63) | TLR8ADORA1CYP2D6DRD1HTR2A | |
| SCHEMBL18109621 | 0.76 | TLR8 (0.70) | TLR8ADORA1CYP2D6DRD1HTR2A | |
| SCHEMBL18109622 | 0.76 | TLR8 (0.70) | TLR8ADORA1CYP2D6DRD1HTR2A | |
| SCHEMBL17829986 | 0.74 | TLR8 (0.64) | TLR8KCNH2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822347-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190330227-A1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330227-A1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | TLR8 1457/4885PDE4A 734/4885PDE4B 706/4885 |
| US-10822347-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | TYMS, TYMP, UMPS | TLR8 1457/4885PDE4A 734/4885PDE4B 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.